Close menu




July 19th, 2021 | 11:11 CEST

BioNTech, Defence Therapeutics, Siemens Healthineers - Winning the fight against cancer

  • Biotechnology
Photo credits: pixabay.com

There are over 200 different types of cancer where degenerate cells begin to form tumors. The cost of the disease is estimated at USD 1,160,000,000,000 worldwide. It is no wonder that a lot of money goes into researching cancer drugs. Whoever makes the breakthrough here can make a lot of money. It would be desirable that one of the three companies presented today could find a solution, as that could save 9.6 million people a year. But it is not only drugs that promise profits but also prevention and diagnostics. Today we highlight three companies that have joined the fight against cancer.

time to read: 4 minutes | Author: Armin Schulz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , DEFENCE THERAPEUTICS INC | CA24463V1013 , SIEMENS HEALTH.AG NA O.N. | DE000SHL1006

Table of contents:


    BioNTech - Phase II launched in skin cancer patients

    When the name BioNTech comes up, most people think directly of the Corona vaccine. The Company stated at the time of the Delta variant outbreak that the vaccine would also protect against it. Since a study published from Israel found only 64% efficacy against the delta variant, boosting via another dose has become a hot topic. The booster is intended to restore protection. On the one hand, this means that the vaccination will probably have to be renewed every 6 months; on the other hand, this is positive for the shareholders since more vaccines will also be needed.

    The Mainz-based biotech Company announced on June 18 that its anti-cancer vaccine would be tested in humans for the first time in a phase II trial. The trial group consists of 120 skin cancer patients and is designed to uncover efficacy and potential side effects. Again, the mRNA method will be used to help the body's defense system fight the degenerated cells. Specific proteins can be used to identify the bad cells. Four other cancer drugs are still in the pipeline.

    Covid-19 has opened the door for the new technology, and now they are trying to fight other diseases through this technology. Without the study from Israel, the share would undoubtedly have seen new highs by now. The uncertainty caused a small price slide from EUR 199 to EUR 163. A double bottom has now been formed there; however, the prospect of more vaccine sales has lured investors again. Last Friday, the share exited trading at EUR 193.75.

    Defence Therapeutics - A promising approach

    The Canadian biotech company has set itself the goal of developing innovative treatment solutions for all people. The basis for this is formed by two different technologies, which the Company owns 100%. There are three main products currently in development based on the Company's proprietary Accum technology. A cancer vaccine derived from dendritic cells, a protein-based vaccine against Covid-19, and antibody-drug conjugates (ADC) against cancer that deliver the drug directly into the affected cells.

    The Accum technology mentioned above enables full scalability of vaccine development for multiple diseases. In tests, 10-fold drug delivery was observed compared to other approved ADC providers. Thus, the Accum platform is an ideal partner for drug treatments. In contrast to radiation therapy, which also attacks healthy cells, Accum therapy only targets the affected cells. As a result, side effects can be significantly reduced.

    The second pillar of Defence Therapeutics is vaccine development. There are numerous potential areas of application for which the patented Accum technology can be used. The platform makes it possible to target the latest viruses and thus combat diseases efficiently. The Company has had initial success in a study on mice. 70% of the mice could be cured despite existing tumors. The share has climbed steeply since its stock market debut on May 7. At the opening, the stock was trading at CAD 1.75 and rose to CAD 7.80. Since then, the stock has been consolidating.

    Siemens Healthineers - Ahead of the quarterly figures

    When the acquisition of US Company Varian Medical Systems for USD 16.4 billion was announced in August 2020, the stock first went on a downward slide. Fears were rife that the Company had paid too much. In the meantime, the wind has changed and new all-time highs have been reached. That's partly due to Covid-19's rapid antigen tests, which have brought in about EUR 750 million in revenue this fiscal year (which ends Sept. 30). Quarterly results are due out on July 30, and more than a few analysts expect the Company to raise its guidance for the current fiscal year.

    The other part of the growth is generated by Varian Medical Systems, as this acquisition has opened up various synergies. The California-based Company specializes in the development of novel cancer screening and treatments. The Company has a 45% market share in hardware and software for cancer medicine. Siemens Healthineers can now cover the entire range of early cancer diagnostics, a competitive advantage, especially in hospital sales. The high margins in cancer care mean that further growth is likely.

    To better focus sales, a sale of the ultrasound equipment division is said to be under discussion. The share has been on an upward trend since the end of October 2020. Inclusion in the new DAX 40 beckons as a reward. Should this succeed, the share would come more into focus, and more investors could jump on board. Currently, one should wait for the figures at the end of July and then think about an investment. The stock has already moved over 20% in the last month and a half and has not yet consolidated.


    All three companies are trying to put a stop to cancer. Due to the high margins, investors can expect large profits in the event of a breakthrough. With biotech companies, one must always expect temporary setbacks. BioNTech has already proven that it is possible to make enormous profits with new technologies. Defence Therapeutics has a very exciting approach that you can invest in before the breakthrough. Siemens Healthineers is focusing more on early detection and can also generate good profits with this.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by André Will-Laudien on May 18th, 2022 | 12:48 CEST

    Biotech stocks: BioNTech, XPhyto Therapeutics, Novavax, Valneva - Crashing, the choice remains difficult!

    • Biotechnology
    • Covid19

    For pure play vaccine companies, the environment is getting tougher. On the one hand, the winter is over, and on the other, Corona has lost its horrors, especially as the Omicron variant presented like a cold for most infected people. 77.6% of the German population have received at least one vaccination dose so far. 63.1 million people have thus already received basic immunization, and 49.5 million people went for another shot. Only 4.6 million people, or 5.5%, have already received a second booster vaccination. 18.6 million people have not been vaccinated, or 22.4% of the population. With currently only 4,000 vaccinations per day, the many millions of vaccine doses ordered are likely to remain on the shelf. For vaccine manufacturers, future orders will plummet. Which Company has a plan B in place?

    Read

    Commented by Juliane Zielonka on May 12th, 2022 | 13:07 CEST

    Cardiol Therapeutics, Tesla, Bayer AG - Instead of trading chronically overvalued shares, treat the chronically ill instead

    • Biotechnology

    No sooner does the US government under Biden seek to influence the Supreme Court in the Monsanto case than the Bayer share slides 7%. But is this share price slide justified? Bayer AG has made provisions for the possible ruling in June and set aside reserves for chronic diseases. Chronic diseases are also a focus of Cardiol Therapeutics. According to the World Health Organization (WHO), the prevalence of chronic diseases increased by 57% worldwide by 2020. Cardiol focuses on heart health in this regard. The share stands at about EUR 1.12 and is seen by analysts at an average of about EUR 7. Meanwhile, Tesla investors are currently experiencing what overvalued shares can do to their portfolios. Their CEO is speculating that he will no longer accept new customers. Why? You can read about it here...

    Read

    Commented by Fabian Lorenz on May 12th, 2022 | 11:12 CEST

    BioNTech, BYD and Desert Gold: Shares for the rebound

    • Gold
    • Electromobility
    • Biotechnology

    Is the rebound coming? After the heavy price losses of recent days and weeks, the market seems ripe for a countermovement. However, this would require a little more volume in the market. But then, especially companies that have not disappointed operationally should profit. BioNTech, for example, belongs to this group. The Company has published convincing figures, and analysts see up to 50% price potential. BYD's share price should also pick up speed again. Finally, the rapid shift to electric pureplay seems to be succeeding and HSBC has raised the price target. Gold was not a safe haven in the current correction. But it is worth looking at bombed-out stocks here as well. Desert Gold Ventures is one of them. The explorer has started a new drill program and secured financing.

    Read